Ovid Therapeutics Inc. · NASDAQ:OVID
Ovid Therapeutics — EILAT XVI Conference on New Antiepileptic Drugs and Devices (May 2022)
12 slides from Ovid Therapeutics's conference presentation, May 23, 2022
Slide 1: OV329: Next generation GABA-AT inhibitor
OV329: Next generation GABA-AT inhibitor Julia Tsai, PhD Senior Vice President, Head of Epilepsy & Clinical Development and Medical Affairs
Slide 2: Disclaimers and forward-looking statements
Disclaimers and forward-looking statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the timing and development of Ovid’s product candidate pipeline and achiev
Slide 3: OV329 shows efficacy in multiple animal models & encouraging safety profile
OV329 shows efficacy in multiple animal models & encouraging safety profile • Effective in multiple acute and chronic animal models of epilepsy/seizures • Preclinical data suggest potential for promising safety profile compared to 1st generation GABA-AT inhibitors • On-track for IND submission and t
Slide 4: Ovid Therapeutics
Ovid Therapeutics Vision: Conquer epilepsies & brain disorders with courageous science • 2 preclinical programs with potential 1st-in-class or best-in-class medicines • Novel mechanisms of action for the potential treatment of epilepsy • Out-licensed novel cholesterol 24-hydroxylase inhibitor to Tak
Slide 5: OV329 is a potent, next-generation GABA-AT inhibitor
OV329 is a potent, next-generation GABA-AT inhibitor • 2022 Epilepsy Foundation Pipeline Conference OV329 facilitates GABA transmission Vigabatrin OV329 Presynaptic Neuron = GABA GAT = GABA • Potential candidate for treatment Glial Cell Glutamine transporter of drug-resistant epilepsy Glutamate Glut
Slide 6: OV329 is active in suppressing seizures in multiple animal models
OV329 is active in suppressing seizures in multiple animal models, including drug-resistant models OV329 Activity Model Injury Model Clinical Correlate Species Dosing (seizure protection) 6 Hz Electrical Stimulation Acute/seizure Acute focal to bilateral tonic-clonic seizure Mouse Acute (0.01, 0.1,
Slide 7: OV329 has anticonvulsant effects in the ivPTZ-induced rat seizure model
OV329 has anticonvulsant effects in the ivPTZ-induced rat seizure model OV329 dose-dependently increases the thresholds of ivPTZ-induced seizures Myoclonus Clonus *Treatment effects calculated as percent change from basal seizure thresholds Data are expressed as mean + SEM, **p<.01; ***p<.001 Feja e
Slide 8: OV329 has anticonvulsant effects in the amygdala-kindled rat model
OV329 has anticonvulsant effects in the amygdala-kindled rat model OV329 increases the afterdischarge threshold, suppresses generalized seizures, and reduces seizure severity in amygdala-kindled rats Afterdischarge threshold Generalized seizure threshold Seizure severity (SS) Seizure severity (ADT)
Slide 9: OV329 has anti-seizure activity in mesial-temporal lobe epilepsy mouse model
OV329 has anti-seizure activity in mesial-temporal lobe epilepsy mouse model of drug resistant epilepsy Vehicle PO OV329 10.0 mg/kg IP ADMIN OV329 10.0 mg/kg PO Vigabatrin 100 mg/kg IP • OV329 achieved a 55% reduction in seizure activity after IP administration • OV329 achieved a 46% reduction after
Slide 10: No ocular effects seen following chronic exposure with OV329 (3 mg/kg)
No ocular effects seen following chronic exposure with OV329 (3 mg/kg) Vehicle OV329 3.0 mg/kg Vigabatrin 300 mg/kg Animal R76 Animal R13 Animal R91 Ocular effects seen in more than No ocular effects seen in 3 mg/kg OV329, q.d. half of rats treated with and vehicle groups in rats at day 45 Vigabatri
Slide 11: Summary: OV329 demonstrated anti-seizure activity at tolerated doses in multiple animal models
Summary: OV329 demonstrated anti-seizure activity at tolerated doses in multiple animal models OV329 is a next-generation GABA-AT inhibitor in development as an anti-seizure medication for rare adult and pediatric epilepsy disorders Non-clinical studies have demonstrated anti-seizure activity of OV3
Slide 12: Thank you
Ovid e Therapeutics Thank you
Ovid Therapeutics — EILAT XVI Conference on New Antiepileptic Drugs and Devices (May 2022) on 6ix